Monopar Therapeutics (MNPR) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monopar Therapeutics (MNPR) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, losing 15.0% versus a loss of 37.2%. Over five years, MNPR leads with a +241.3% price change compared with -79.1% for PHAT. Monopar Therapeutics is the larger company by market cap ($562.3 million vs $550.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNPR | PHAT |
|---|---|---|
| Share price | $83.78 | $6.81 |
| Market cap | $562.35M | $550.94M |
| 1-day change | +5.29% | +0.44% |
| YTD return | +28.30% | -58.95% |
| 1-year return | -14.96% | -37.18% |
| 5-year return | +241.26% | -79.05% |
| Forward P/E | — | 6.33 |
| EPS (TTM) | $-2.20 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $124.82 | $18.31 |
| 52-week low | $50.07 | $6.52 |
| Distance from 52-week high | -32.88% | -62.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +55.07% | +200.29% |
| Average volume | 218.50K | 1.39M |
| Shares outstanding | 6.71M | 80.90M |
| Employees | 22 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNPR has outperformed PHAT by 22.2 percentage points over the past year.
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
MNPR vs PHAT FAQ
Which is bigger, Monopar Therapeutics or Phathom Pharmaceuticals?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $562.35M compared with $550.94M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, MNPR or PHAT?
MNPR returned -14.96% over the past 12 months, compared with -37.18% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Monopar Therapeutics and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.